A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
NCT01992653
Completed
This multicenter, open-label, dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of polatuzumab vedotin in combination with rituximab or obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (CHP chemotherapy) in participants with non-Hodgkin's lymphoma (NHL). Participants will receive escalating doses of polatuzumab vedotin intravenously (IV) every 3 weeks in combination with standard doses of rituximab plus CHP chemotherapy (R-CHP) or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2023
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +10 locations
Conditions: Lymphoma, Non Hodgkin
Register for Updates
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
NCT02224872
Completed
Our primary objective is to determine if it is feasible for SAA patients to be transplanted using non-myeloablative conditioning and post transplantation cyclophosphamide with partially HLA-mismatched donors.
Gender:
ALL
Ages:
73 years and below
Trial Updated:
03/08/2023
Locations: The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Severe Aplastic Anemia, Bone Marrow Failure Syndromes
Register for Updates
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01256398
Completed
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Stanford Cancer Institute Palo Alto, Palo Alto, California +100 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Unknown
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Arrowhead Regional Medical Center, Colton, California +42 locations
Conditions: HER2-negative Breast Cancer
Register for Updates
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
NCT02345850
Completed
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation.
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
03/02/2023
Locations: City of Hope National Medical Center, Duarte, California +27 locations
Conditions: Acute Leukemia, Myelodysplasia
Register for Updates
TAC Versus TC for Adjuvant Breast Cancer
NCT00493870
Completed
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
02/28/2023
Locations: Birmingham Hematology and Oncology, Birmingham, Alabama +94 locations
Conditions: Breast Cancer
Register for Updates
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
NCT05622058
Terminated
This is a Phase 1b open-label, single arm, multicenter, study of ALRN-6924 as a chemoprotection agent in patients with TP53-mutated HER2- breast cancer (stages IIa to IIIb) receiving neoadjuvant or adjuvant chemotherapy with doxorubicin, docetaxel, and cyclophosphamide (TAC). Chemotherapy affects cells that are dividing, whether they are tumor cells or healthy cells (including, bone marrow cells, hair follicle cells, and epithelial cells lining the gastrointestinal tract). ALRN-6924 is designed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2023
Locations: Oncology and Hematology Associates of West Broward, Tamarac, Florida +13 locations
Conditions: Prevention of Chemotherapy-induced Myelosuppression
Register for Updates
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02960646
Completed
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Register for Updates
Cabozantinib With Topotecan-Cyclophosphamide
NCT04661852
Completed
This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. * The names of the drugs are: * Cabozantinib * Topotecan * Cyclophosphamide * The names of the non-investigational supportive care drugs are: * Filgrastim, pegfilgrastim, or a related growth factor.
Gender:
ALL
Ages:
Between 6 years and 30 years
Trial Updated:
02/13/2023
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Register for Updates
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
NCT01746173
Terminated
The current standard of care for the frontline treatment of peripheral T-cell lymphomas (PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT). However, many patients are unable to get to ASCT or relapse after ASCT, with a poor prognosis. Recently, a novel ASCT conditioning regimen of gemcitabine, busulfan and melphalan (Gem/Bu/Mel) has been reported to lead to favorable outcomes in this disease. We therefore designed a frontline regimen of CHOEP induction follo... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/26/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: T-cell Non-Hodgkin Lymphoma
Register for Updates
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
NCT00589316
Terminated
This phase I trial studies the side effects and best dose of iodine I 131monoclonal antibody BC8 when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, and donor bone marrow transplant, and to see how well they work in treating patients with acute myeloid leukemia or acute lymphoblastic leukemia that has spread to nearby or other places in the body (advanced), or high-risk myelodysplastic syndrome. Giving chemotherapy drugs, such as fludarabine phosphate and cy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2023
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Register for Updates
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
NCT03252600
Unknown
This randomized phase II trial studies how well lenalidomide, dexamethasone, and eotuzumab with or without cyclophosphamide work in treating patients with primary amyloidosis that has come back after a period of improvement. Drugs used in chemotherapy, such as lenalidomide, dexamethasone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +4 locations
Conditions: Recurrent Primary Amyloidosis
Register for Updates